Nectar Lifesciences Complete Financial Statements
In FY2026, Nectar Lifesciences (NECLIFE) reported revenue ₹6 Cr, net profit ₹-68 Cr and EPS ₹-3.38, with a net profit margin of -1133.3% and ROE of -11.7%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review NECLIFE P/E comparison to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
NECLIFE Revenue, Net Profit & EBITDA — Year-on-Year Growth
NECLIFE YoY (Mar 2025 vs Mar 2026), net profit +47.7%, EBITDA +36.2%, expenses -31.5%. For live price, earnings ratios and company overview, see NECLIFE share price.
NECLIFE Income Statement — Revenue, EBITDA & Net Profit
Nectar Lifesciences revenue ₹6 Cr, EBITDA ₹-83 Cr, net profit ₹-68 Cr, EPS ₹-3.38 (2026) — net profit margin -1133.3%. Explore NECLIFE investment value to estimate fundamental worth using multiple valuation models.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 0 | 0 | 6 | 36 | 12 | 441 | 359 | 8 | 409 | 406 | 395 | 453 | 399 | 477 | 403 | 357 | 370 | 351 | 390 | 444 | 427 | 565 | 390 | 378 | 580 | 797 | 578 | 649 | 725 | 532 | 734 |
| Expenses | 89 | 177 | 130 | 69 | 2 | 6 | 393 | 320 | 0 | 371 | 371 | 359 | 410 | 396 | 427 | 361 | 343 | 337 | 345 | 350 | 396 | 397 | 511 | 373 | 345 | 531 | 721 | 513 | 592 | 660 | 471 | 667 |
| EBITDA | -83 | -176 | -130 | -63 | 34 | 6 | 49 | 40 | 8 | 38 | 35 | 36 | 43 | 3 | 50 | 42 | 15 | 33 | 6 | 41 | 47 | 31 | 54 | 17 | 33 | 49 | 76 | 64 | 57 | 66 | 62 | 67 |
| Operating Profit Margin % | 0.00% | 0.00% | 0.00% | -1212.00% | 0.00% | -10.00% | 11.00% | 11.00% | 0.00% | 7.00% | 4.00% | 9.00% | 9.00% | -2.00% | 10.00% | 10.00% | 0.00% | 8.00% | 1.00% | 9.00% | 11.00% | 7.00% | 10.00% | 4.00% | 9.00% | 8.00% | 9.00% | 11.00% | 9.00% | 9.00% | 11.00% | 9.00% |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 15 | 16 | 0 | 15 | 15 | 15 | 15 | 15 | 14 | 15 | 15 | 14 | 15 | 14 | 14 | 15 | 15 | 15 | 15 | 14 | 15 | 16 | 15 | 16 | 16 | 17 |
| Interest | 6 | 0 | 0 | 0 | 30 | 0 | 24 | 20 | 0 | 21 | 20 | 18 | 25 | 21 | 17 | 21 | 18 | 18 | 26 | 26 | 18 | 28 | 31 | 28 | 31 | 33 | 39 | 32 | 31 | 44 | 30 | 36 |
| Profit Before Tax | -88 | -176 | -130 | -64 | 3 | 6 | 11 | 5 | 8 | 2 | 2 | 3 | 3 | -33 | 18 | 6 | -18 | 0 | -36 | 1 | 15 | -11 | 8 | -26 | -12 | 3 | 23 | 16 | 10 | 7 | 15 | 14 |
| Tax | -20 | 0 | 0 | 0 | -11 | 0 | 11 | 2 | 0 | 1 | -2 | 1 | 1 | -10 | 6 | 2 | -8 | -2 | 5 | -1 | 6 | -4 | 1 | -9 | -4 | 0 | 5 | 3 | 2 | 1 | 2 | 3 |
| Net Profit | -68 | -176 | -130 | -63 | 14 | 6 | 1 | 3 | 8 | 1 | 4 | 2 | 2 | -23 | 12 | 4 | -9 | 2 | -41 | 2 | 10 | -7 | 7 | -17 | -8 | 3 | 18 | 14 | 8 | 6 | 13 | 11 |
| Earnings Per Share (₹) | -3.38 | -7.85 | -5.80 | -2.82 | 0.64 | 0.25 | 0.03 | 0.13 | 0.35 | 0.05 | 0.16 | 0.08 | 0.07 | -1.00 | 0.52 | 0.17 | -0.41 | 0.08 | -1.83 | 0.08 | 0.43 | -0.33 | 0.33 | -0.75 | -0.36 | 0.11 | 0.78 | 0.61 | 0.37 | 0.26 | 0.59 | 0.49 |
NECLIFE Balance Sheet — Assets, Liabilities & Shareholders' Equity
NECLIFE total assets ₹622 Cr, total equity ₹582 Cr, total liabilities ₹ Cr (2026) — ROE -11.7%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 622 | 2,047 | 2,191 | 2,189 | 2,391 | 2,471 | 2,633 | 2,705 | 2,724 | 2,581 | 2,556 | 2,511 |
| Current Assets | 289 | 1,238 | 1,284 | 1,231 | 1,355 | 1,239 | 1,615 | 1,669 | 1,661 | 1,496 | 1,464 | 1,369 |
| Fixed Assets | 103 | 633 | 643 | 662 | 723 | 772 | 785 | 825 | 852 | 881 | 906 | 934 |
| Capital Work in Progress | 0 | 57 | 66 | 78 | 85 | 99 | 115 | 100 | 100 | 102 | 99 | 91 |
| Investments | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| Other Assets | 0 | 1,357 | 1,482 | 1,449 | 1,582 | 1,600 | 1,733 | 1,780 | 1,771 | 1,597 | 1,551 | 1,485 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 9 | 70 | 149 | 234 | 299 | 222 | 249 | 300 | 356 | 296 | 362 | 397 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 582 | 956 | 1,069 | 1,065 | 1,088 | 1,062 | 1,136 | 1,105 | 1,059 | 1,007 | 954 | 958 |
| Share Capital | 19 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves & Surplus | 563 | 934 | 1,047 | 1,042 | 1,066 | 1,040 | 1,114 | 1,083 | 1,036 | 984 | 932 | 936 |
NECLIFE Cash Flow Statement — Operating, Investing & Financing
Nectar Lifesciences operating cash flow ₹169 Cr, investing ₹-42 Cr, financing ₹-128 Cr, net cash flow ₹-1 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 169 | 225 | 134 | 95 | 21 | 285 | 239 | 65 | 199 | 169 | 144 |
| Investing Activities | -42 | -17 | 52 | 17 | -29 | -33 | -26 | -29 | -18 | -77 | -60 |
| Financing Activities | -128 | -205 | -186 | -119 | 12 | -252 | -201 | -40 | -204 | -89 | -62 |
| Net Cash Flow | -1 | 2 | 0 | -8 | 4 | 0 | 12 | -4 | -24 | 3 | 23 |